Catalyst

Slingshot members are tracking this event:

Neurocrine Biosciences Expects to File NDA for NBI-98854 (valbenazine) in 2016

Source Link:
http://phoenix.corporate-ir.net/phoenix.zhtml?c=68817&p=IROL-secToc&TOC=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9vdXRsaW5lLnhtbD9yZXBvPXRlbmsmaXBhZ2U9MTA3MzI3NjMmc3Vic2lkPTU3&ListAll=1&sXBRL=1

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
NBIX
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details Neurocrine Biosciences expects to file and NDA for valbenazine in 2016.  The filing will be based off the Kinect 3 Phase 3 study that is currently in the safety extension portion of the study but has shown positive data for the drug.  
http://phoenix.corpo...
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Aug 29, 2016
Occurred Source:
http://phoenix.corporate-ir.net/phoenix.zhtml?c=68817&p=irol-newsArticle&ID=2197989
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Nda Filing, Nbi-98854, Valbenazine, Tardive Dyskinesia
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.